Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.

Autor: El Andari J; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany., Renaud-Gabardos E; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., Tulalamba W; Department of Gene Therapy and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels 1090, Belgium., Weinmann J; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany., Mangin L; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., Pham QH; Department of Gene Therapy and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels 1090, Belgium., Hille S; University Hospital Schleswig-Holstein, Campus Kiel, Innere Medizin III, 24105 Kiel, Germany.; German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Kiel, Germany., Bennett A; Department of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA., Attebi E; Genethon, 91000 Evry, France., Bourges E; Genethon, 91000 Evry, France., Leborgne C; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., Guerchet N; Genethon, 91000 Evry, France., Fakhiri J; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany., Krämer C; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany., Wiedtke E; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany., McKenna R; Department of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA., Guianvarc'h L; Genethon, 91000 Evry, France., Toueille M; Genethon, 91000 Evry, France., Ronzitti G; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., Hebben M; Genethon, 91000 Evry, France., Mingozzi F; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., VandenDriessche T; Department of Gene Therapy and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels 1090, Belgium.; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven 3000, Belgium., Agbandje-McKenna M; Department of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA., Müller OJ; University Hospital Schleswig-Holstein, Campus Kiel, Innere Medizin III, 24105 Kiel, Germany.; German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Kiel, Germany., Chuah MK; Department of Gene Therapy and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels 1090, Belgium.; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven 3000, Belgium., Buj-Bello A; Genethon, 91000 Evry, France.; Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France., Grimm D; Medical Faculty, Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Cluster of Excellence CellNetworks, University of Heidelberg, 69120 Heidelberg, Germany.; BioQuant, University of Heidelberg, 69120 Heidelberg, Germany.; German Center for Infection Research (DZIF) and German Center for Cardiovascular Research (DZHK), partner site Heidelberg, Heidelberg, Germany.

Publikováno v: Science advances [Sci Adv] 2022 Sep 23; Vol. 8 (38), pp. eabn4704. Date of Electronic Publication: 2022 Sep 21.

Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.

Autor: Collaud F; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Bortolussi G; International Center for Genetic Engineering and Biotechnology, 34149 Trieste, Italy., Guianvarc'h L; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Aronson SJ; Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, AG&M, 1105 BK Amsterdam, the Netherlands., Bordet T; AFM-Telethon, 91000 Evry, France., Veron P; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Charles S; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Vidal P; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Sola MS; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Rundwasser S; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Dufour DG; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Lacoste F; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Luc C; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Wittenberghe LV; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Martin S; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Le Bec C; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Bosma PJ; Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, AG&M, 1105 BK Amsterdam, the Netherlands., Muro AF; International Center for Genetic Engineering and Biotechnology, 34149 Trieste, Italy., Ronzitti G; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Hebben M; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France., Mingozzi F; INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2018 Dec 31; Vol. 12, pp. 157-174. Date of Electronic Publication: 2018 Dec 31 (Print Publication: 2019).

The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.

Autor: Léon A; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France. Electronic address: arnaud.leon@valneva.com., David AL; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Madeline B; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Guianvarc'h L; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Dureau E; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Champion-Arnaud P; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Hebben M; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France., Huss T; Transgene SA, 400 boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166, 67405 Illkirch Graffenstaden cedex, France., Chatrenet B; Virbac Animal, Health, 13ème rue LID, 06515 Carros, France., Schwamborn K; Valneva SE, 6 rue Alain Bombard, 44800 Saint-Herblain, France.

Publikováno v: Vaccine [Vaccine] 2016 Nov 21; Vol. 34 (48), pp. 5878-5885. Date of Electronic Publication: 2016 Oct 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Autor: Wang, Yuxiang¹ (AUTHOR) yuxiang.wang@nih.gov

Publikováno v: Viruses (1999-4915). Aug2023, Vol. 15 Issue 8, p1742. 20p.